Vixtimotamab (AMV-564, TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively engages human CD33 and CD3 antigens. It is utilized in research on acute myeloid leukemia (AML) [1].
Target:
AMV-564 , TandAb T564
* VAT and and shipping costs not included. Errors and price changes excepted
